3 completed, 1 active not recruiting. 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Completed 3, Active not recruiting 1 |
Follow compound 21: new trials by email Literature Review of compound 21 trials Research Report on compound 21
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Trial to Evaluate Efficacy and Safety of Buloxibutid in People With Idiopathic Pulmonary Fibrosis. Buloxibutid, Placebo - Idiopathic Pulmonary Fibrosis (IPF) | Phase 2 | Active not recruiting | Vicore Pharma AB | 378 | 2024-12-09 | 2026-10-29 |
| Safety, Efficacy and Pharmacokinetics of C21 in Subjects With IPF C21 - Idiopathic Pulmonary Fibrosis | Phase 2 | Completed | Vicore Pharma AB | 52 | 2020-11-13 | 2025-05-23 |
| Safety and Efficacy of C21 in Subjects With COVID-19 C21, Placebo - COVID-19 | Phase 2 | Completed | Vicore Pharma AB | 206 | 2020-07-21 | 2021-06-23 |
| Cold Challenge With C21 in RP C21, Placebo - Raynaud Phenomenon, Systemic Sclerosis | Phase 2 | Completed | Vicore Pharma AB | 20 | 2020-01-03 | 2023-05-18 |
Idiopathic Pulmonary Fibrosis (2) · COVID-19 (1) · Raynaud Disease (1) · Scleroderma, Systemic (1)
Vicore Pharma AB (4)
United Kingdom (4) · India (2) · Argentina (1) · Australia (1) · Austria (1) · Belgium (1) · Canada (1) · Germany (1) · Greece (1) · Italy (1) · Mexico (1) · Poland (1) · Russia (1) · South Korea (1) · Taiwan (1)
Joanna Porter, MD (2) · Ariane Herrick, MD (1)
2019 (1)